Day: February 5, 2018

Sagar Lonial.

Results Patients Between June 2011 and November 2012 at 168 sites globally Patients were enrolled. In total, 646 patients underwent randomization . Baseline characteristics were balanced between your two study groups ., and Desk S1 in the Supplementary Appendix). Approximately one third of sufferers had resistance with their most recent line of therapy, including bortezomib and thalidomide . A total of 32 percent of sufferers had the del variant , which is connected with an unhealthy outcome. Efficacy A total of 113 of 321 patients in the elotuzumab group and 66 of 325 patients in the control group were still receiving research treatment during the cutoff date for the interim analysis on November 4, 2014. Read More